已收盤 11-20 16:00:00 美东时间
+1.770
+1.11%
Revolution Medicines (RVMD) is back in focus after fresh Phase 1/2 data for RASONQUE in metastatic pancreatic cancer, along with recent FDA and European Commission approvals for the drug. For context, Revolution Medicines now trades at US$161.20, with the share price giving up 14.1% over the past 30 days and 23% over 3 months, even as the year to date share price return sits at 104% and the 1 year total shareholder return reaches 127.5%. Multi ye
今天 08:11
Revolution Medicines reported updated Phase 1/2 RMC-GI-102 data showing a 60.7% confirmed objective response rate for RASONQUE plus chemotherapy in first-line metastatic pancreatic cancer, alongside prior U.S. and new European Union approvals in previously treated patients. The combination of strong early efficacy signals in an initial treatment setting and expanded European marketing authorization places real-world uptake, safety management cost
11-21 07:14
Erasca, Inc. announced positive updated U.S. Phase 1 monotherapy and initial combination data for ERAS-0015, a pan-RAS molecular glue, in patients with RAS-mutant solid tumors. ERAS-0015 demonstrated strong anti-tumor activity across multiple tumor types, including 44% confirmed ORR in KRAS G12X pancreatic ductal adenocarcinoma (PDAC) and 69% in G12D or G12V PDAC, with favorable safety profiles. The company plans to initiate potentially registrat...
11-20 12:00
11月17日,RVMDW(RVMDW)收跌12.7%,报7.12美元,成交额4.06万美元,市值13.77亿美元。 行情数据 • 开盘价:7.81美元 • 最高...
11-17 06:34
11月17日,Revolution Medicines(RVMD)收跌3.15%,报166.87美元,成交额4.2亿美元,市值360.93亿美元。 行情数据 ...
11-17 05:39
今日重点评级关注:Canaccord Genuity:维持Fractyl Health"买入"评级,目标价从39美元升至40美元;HC Wainwright & Co.:维持Fractyl Health"买入"评级,目标价从8美元升至24美元
11-16 20:14
最新披露的机构持仓数据显示,UBS AG于最新季度调整了对Revolution Medicines(RVMD)的持仓。 主要变动如下: 持仓变化:减持-86...
11-16 16:30
Morgan Stanley analyst Sean Laaman maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and lowers the price target from $272 to $247.
11-14 02:05
11月10日,Revolution Medicines(RVMD)收涨4.09%,报200.15美元,成交额5.08亿美元,市值432.91亿美元。 行情数据...
11-10 05:39
(来源:药研网) 11 月 9 日,CDE 官网公示,百济神州(BeOne Medicines)申报的 daraxonrasib 片拟纳入优先审评,拟定适应症为...
11-09 17:47